Home » Stocks » AGN

Allergan plc (AGN)

May 8, 2020 - AGN was delisted after being acquired by ABBV
Stock Price: $193.02 USD 0.00 (0.00%)
Updated May 8, 2020 4:00 PM EDT
Market Cap 63.66B
Revenue (ttm) 16.10B
Net Income (ttm) -2.49B
Shares Out 328.28M
EPS (ttm) -7.57
PE Ratio n/a
Forward PE 11.89
Dividend $2.96
Dividend Yield 1.53%
Trading Day May 8, 2020
Last Price $193.02
Previous Close $193.02
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 191.64 - 193.38
Day's Volume 0
52-Week Range 114.27 - 202.22

News

Hide News
Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.

Zacks Investment Research - 5 months ago

The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products

Other stocks mentioned: TEVA
Reuters - 5 months ago

New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.

Other stocks mentioned: TEVA
PRNewsWire - 5 months ago

DUBLIN, Aug. 14, 2020 /PRNewswire/ -- The "Global Breast Implant Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

GuruFocus - 7 months ago

John Paulson (Trades, Portfolio)’s Paulson & Co. sold shares of the following stocks during the first quarter of 2020.

Other stocks mentioned: DISCA, DISCB, DISCK, S
CNBC Television - 8 months ago

Abbvie CEO on Allergan acquisition, Covid-19's effect on demand and more

Abbvie CEO Richard Gonzalez joins "Squawk on the Street" to discuss the company's acquisition of Allergan, why the coronavirus pandemic has led to a demand curve, the effectiveness of migraine...

Other stocks mentioned: ABBV
Investors Business Daily - 8 months ago

AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?

Other stocks mentioned: ABBV
Market Watch - 8 months ago

Allergan PLC AGN, +0.01% said late Friday that AbbVie Inc. ABBV, -0.30% has closed its acquisition of the company.

Other stocks mentioned: ABBV
Seeking Alpha - 8 months ago

AbbVie: Redeploy The Allergan Cash

Other stocks mentioned: ABBV
The Motley Fool - 8 months ago

With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.

Other stocks mentioned: ABBV
Investors Business Daily - 8 months ago

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Other stocks mentioned: ABBV, BMY, GRFS, JAZZ, MRK, NVO, SNY, ZTS
Market Watch - 8 months ago

The deal for AbbVie Inc. ABBV, +4.28% to buy Allergan Plc. AGN, +2.16% has cleared an antitrust hurdle, the companies said late Tuesday.

Other stocks mentioned: ABBV
CNBC Television - 8 months ago

Final Trades: JPM, GDX, AAPL & AGN

The Fast Money traders offer up their final trades of the week.

Other stocks mentioned: AAPL, GDX, JPM
Zacks Investment Research - 8 months ago

On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

InvestorPlace - 8 months ago

Don't let the pandemic distract your attention from a monster acquisition - and a chance to own AGN stock before the deal's finalized. The post Buy Allergan Stock as Big Pharma’s Biggest Deal ...

Zacks Investment Research - 8 months ago

Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 8 months ago

The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.

Other stocks mentioned: ABBV
The Motley Fool - 9 months ago

And two of the three offer nice dividends, too.

Other stocks mentioned: ABBV, ABT, BMY
Zacks Investment Research - 9 months ago

Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently...

Other stocks mentioned: ARR, COOP, ITB, MORT, PPH, TPH, XLF
The Motley Fool - 9 months ago

The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.

Other stocks mentioned: ABBV, BMY, LLY, MYL, PFE
The Motley Fool - 10 months ago

The blockbuster pharmaceutical deal has had its share of detractors.

Other stocks mentioned: ABBV
Market Watch - 10 months ago

AbbVie Inc. ABBV, -1.68% and Allergan PLC AGN, +4.34% announced Tuesday that they signed a consent decree with the U.S.

Other stocks mentioned: ABBV
Zacks Investment Research - 10 months ago

Allergan (AGN) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 10 months ago

AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

Other stocks mentioned: ABBV
Zacks Investment Research - 10 months ago

Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

Zacks Investment Research - 10 months ago

Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.

Other stocks mentioned: EDIT
The Motley Fool - 10 months ago

It's the first time this type of gene-editing treatment has been tested on a human.

Other stocks mentioned: EDIT
GlobeNewsWire - 10 months ago

AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients

Other stocks mentioned: EDIT
The Motley Fool - 10 months ago

There are a few potential backup plans. But all of them have drawbacks.

Other stocks mentioned: ABBV
The Motley Fool - 11 months ago

The pharmaceutical giant stands accused of making false and misleading product comparisons.

The Motley Fool - 11 months ago

The groups are worried about reduced competition if the merger goes through.

Other stocks mentioned: ABBV
Reuters - 11 months ago

A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S.

Other stocks mentioned: ABBV
Seeking Alpha - 11 months ago

Allergan + Cash Becomes More Compelling - February 12 Update

The Motley Fool - 11 months ago

It's all about the lips with the soon-to-be-acquired company's latest advertising push.

Zacks Investment Research - 11 months ago

Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

InvestorPlace - 11 months ago

Allergan (AGN) earnings for the pharmaceutical company's fourth quarter of 2019 have AGN stock up Monday after beating estimates.

The Motley Fool - 11 months ago

The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.

The Motley Fool - 11 months ago

The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.

Benzinga - 11 months ago

Allergan plc (NYSE: AGN) reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%.

Zacks Investment Research - 11 months ago

Allergan (AGN) delivered earnings and revenue surprises of 13.23% and 6.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Market Watch - 11 months ago

Shares of Allergan PLC AGN, +2.16% rose 1% in premarket trading Monday, after the drug maker reported a fourth-quarter adjusted profit and revenue that beat expectations.

Investors Business Daily - 11 months ago

Allergan earnings beat Q4 estimates. Shares rose modestly before the open.

CNBC Television - 11 months ago

Jim Cramer previews the week ahead of earnings reports from Allergan, Lyft, Nvidia and more companies

CNBC's Jim Cramer gives a preview of what he's looking for in corporate earnings reports in the coming week.

Other stocks mentioned: LYFT, NVDA
Zacks Investment Research - 11 months ago

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.

Zacks Investment Research - 11 months ago

Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.

Other stocks mentioned: ABBV
The Motley Fool - 11 months ago

A pair of deals will remove some regulatory impediments to the merger.

Other stocks mentioned: ABBV
24/7 Wall Street - 11 months ago

This is already a huge week for earnings, as nearly half of the Dow Jones industrial average is reporting, and roughly 150 companies in the S&P 500 as well.

Other stocks mentioned: BIIB, PFE
Reuters - 11 months ago

U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.

Other stocks mentioned: ABBV, NSRGY, AZN
The Motley Fool - 11 months ago

The clock's ticking on this big pharmaceutical buyout.

Other stocks mentioned: ABBV

About AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also o... [Read more...]

Industry
Drug Manufacturers—General
IPO Date
Feb 17, 1993
Stock Exchange
NYSE
Ticker Symbol
AGN
Full Company Profile

Financial Performance

In 2019, Allergan's revenue was $16.09 billion, an increase of 1.91% compared to the previous year's $15.79 billion. Losses were -$5.27 billion, 3.43% more than in 2018.

Financial Statements